title: Role of capecitabine in treating metastatic colorectal cancer in Chinese patients.
abstract: The China Food and Drug Administration approved the use of capecitabine in patients with metastatic colorectal cancer (mCRC) in 2004. This paper reviews the available information of capecitabine in Chinese patients with mCRC, focusing on its effectiveness and safety against mCRC. Identification of all eligible studies was made by searching the PubMed and Wanfang database from 2000 to 2013. Published data examining various aspects of clinical response and tolerability with capecitabine alone or in combination with other chemotherapeutic or biological agents for first- and second-line mCRC were examined. Capecitabine and its combination displayed high efficacy in Chinese patients with mCRC. Toxicities are generally manageable, and elderly patients can tolerate capecitabine well.
authors.affiliation: Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.
authors.forename: Feng
authors.initials: F
authors.lastname: Wang
authors.affiliation: Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.
authors.forename: Feng-Hua
authors.initials: FH
authors.lastname: Wang
authors.affiliation: Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.
authors.forename: Long
authors.initials: L
authors.lastname: Bai
authors.affiliation: Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.
authors.forename: Rui-Hua
authors.initials: RH
authors.lastname: Xu
keywords: Chinese; capecitabine; metastatic colorectal cancer
references.citation: J Cancer Res Clin Oncol. 2010 Apr;136(4):503-10
references.pmid: 19777259
references.citation: J Clin Oncol. 2007 Sep 20;25(27):4217-23
references.pmid: 17548840
references.citation: J Clin Oncol. 2004 Jun 1;22(11):2078-83
references.pmid: 15169794
references.citation: Innate Immun. 2009 Feb;15(1):33-41
references.pmid: 19201823
references.citation: Oncology (Williston Park). 2012 Sep;26(9):842, 873
references.pmid: 23061342
references.citation: J Clin Oncol. 2007 Oct 20;25(30):4779-86
references.pmid: 17947725
references.citation: Clin Pharmacokinet. 2001;40(2):85-104
references.pmid: 11286326
references.citation: Eur J Cancer. 1998 Jul;34(8):1274-81
references.pmid: 9849491
references.citation: Oncologist. 2006 Oct;11(9):981-7
references.pmid: 17030638
references.citation: BMC Cancer. 2011 Jul 09;11:288
references.pmid: 21740590
references.citation: CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
references.pmid: 15761078
references.citation: Oncologist. 2007 Feb;12(2):152-5
references.pmid: 17296810
references.citation: Br J Cancer. 2011 Jun 28;105(1):58-64
references.pmid: 21673685
references.citation: Med Oncol. 2013;30(3):604
references.pmid: 23686699
references.citation: J Clin Oncol. 2001 Nov 1;19(21):4097-106
references.pmid: 11689577
references.citation: J Clin Oncol. 1997 Feb;15(2):808-15
references.pmid: 9053508
references.citation: J Clin Oncol. 2008 Apr 20;26(12):2013-9
references.pmid: 18421054
references.citation: Cancer Biol Med. 2012 Jun;9(2):111-4
references.pmid: 23691464
references.citation: J Clin Oncol. 2005 Jul 10;23(20):4553-60
references.pmid: 16002847
references.citation: Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1688-94
references.pmid: 19505900
references.citation: Zhonghua Yu Fang Yi Xue Za Zhi. 2012 Jul;46(7):598-603
references.pmid: 22943913
references.citation: Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4082-5
references.pmid: 7513432
references.citation: Ann Oncol. 2008 Oct;19(10):1720-6
references.pmid: 18550577
references.citation: J Clin Oncol. 2008 Jul 20;26(21):3523-9
references.pmid: 18640933
references.citation: Cancer Res. 1999 Jan 1;59(1):189-97
references.pmid: 9892206
references.citation: Zhonghua Wai Ke Za Zhi. 2005 May 1;43(9):557-60
references.pmid: 15938923
references.citation: Jpn J Clin Oncol. 2010 Jan;40(1):10-6
references.pmid: 19773270
references.citation: Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2010 Aug;32(4):417-20
references.pmid: 20868601
references.citation: Lancet. 2013 Jan 26;381(9863):303-12
references.pmid: 23177514
references.citation: Cancer Chemother Pharmacol. 2000;45(4):291-7
references.pmid: 10755317
references.citation: Oncogene. 2004 Aug 23;23(38):6329-40
references.pmid: 15322508
references.citation: Zhonghua Zhong Liu Za Zhi. 2004 Feb;26(2):119-21
references.pmid: 15059335
references.citation: J Clin Oncol. 2001 Apr 15;19(8):2282-92
references.pmid: 11304782
references.citation: Clin Oncol (R Coll Radiol). 2008 Mar;20(2):168-75
references.pmid: 18155454
references.citation: World J Gastroenterol. 2010 Feb 28;16(8):960-5
references.pmid: 20180234
references.citation: Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2009 Jun;31(3):358-61
references.pmid: 19621525
references.citation: J Clin Oncol. 2007 Sep 20;25(27):4224-30
references.pmid: 17548839
references.citation: J Clin Oncol. 2010 Apr 20;28(12):2077-84
references.pmid: 20308672
references.citation: Ann Surg Oncol. 2000 Jul;7(6):441-9
references.pmid: 10894140
references.citation: Int J Cancer. 2011 Feb 1;128(3):682-90
references.pmid: 20473862
references.citation: Zhongguo Fei Ai Za Zhi. 2005 Aug 20;8(4):283-90
references.pmid: 21108883
references.citation: Ann Oncol. 2008 May;19(5):920-6
references.pmid: 18065406
references.citation: Cancer Epidemiol Biomarkers Prev. 2003 Mar;12(3):201-8
references.pmid: 12646508
references.citation: Clin Cancer Res. 2013 Apr 15;19(8):1920-5
references.pmid: 23444216
references.citation: Br J Cancer. 2004 Mar 22;90(6):1190-7
references.pmid: 15026800